$CLDX,STATE STREET CORP Total Shares: 8,561,225 Ha
Post# of 22707
http://www.statestreet.com/home.html
STATE STREET CORP Total Shares: 8,561,225 Has Stake in Celldex Therapeutics, Inc. (CLDX)
Posted by paymon on Apr 8th, 2016 // No Comments
Celldex Therapeutics logo
STATE STREET CORP
Total Shares:
8,561,225
disclosed that they own 8.7% of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Friday, April 8th. The investor owns 8,561,225 shares of the stock worth $40,323,370. The filing is available through Edgar at this link.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. DekaBank Deutsche Girozentrale increased its position in shares of Celldex Therapeutics by 1.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 50,100 shares of the biopharmaceutical company’s stock valued at $808,000 after buying an additional 500 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Celldex Therapeutics by 1.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 64,690 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 662 shares in the last quarter. Bedell Frazier Investment Counseling LLC raised its position in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares in the last quarter. Tocqueville Asset Management L.P. raised its position in Celldex Therapeutics by 54.9% in the fourth quarter. Tocqueville Asset Management L.P. now owns 73,400 shares of the biopharmaceutical company’s stock worth $1,151,000 after buying an additional 26,000 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares in the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded down 0.42% during trading on Friday, reaching $4.69. The company had a trading volume of 1,957,980 shares. The company has a 50-day moving average of $4.98 and a 200-day moving average of $10.93. The firm’s market capitalization is $462.92 million. Celldex Therapeutics, Inc. has a 52-week low of $2.96 and a 52-week high of $30.28.
Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.02. During the same period in the prior year, the business earned ($0.36) EPS. The firm earned $1.80 million during the quarter, compared to the consensus estimate of $0.80 million. The company’s revenue for the quarter was up 21.1% compared to the same quarter last year. Analysts expect that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current fiscal year.
CLDX has been the topic of several analyst reports. Wedbush downgraded Celldex Therapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 target price on the stock. in a research note on Monday, March 7th. Jefferies Group downgraded Celldex Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $31.00 to $4.00 in a report on Monday, March 7th. Zacks Investment Research cut shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 4th. Guggenheim downgraded shares of Celldex Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, March 7th. Finally, HC Wainwright reduced their target price on shares of Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, March 8th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
(0)
(0)
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
![937206596_images.jpg](https://investorshangout.com/images/MYImages/937206596_images.jpg)